One in Five Adults in the UAE Has Diabetes. In Saudi Arabia It Is Closer to One in Four
IDF figures put UAE adult prevalence at 20.7 per cent and Saudi Arabia at 23.1 per cent, against a global figure around a tenth. The explanation is not one thing, and one of the contributing factors is barely three generations old.
Thursday, July 16, 2026/4 min read

Start with the numbers, because they are the argument.
The International Diabetes Federation's figures for 2024 put adult diabetes prevalence in the United Arab Emirates at 20.7 per cent, which works out at around 1,274,200 people from an adult population of 7,710,700. Saudi Arabia sits at 23.1 per cent. Globally, the IDF's eleventh Atlas counts 589 million adults living with diabetes.
The Middle East and North Africa carries the highest regional prevalence of any IDF region. This is not a modest local variation. On a per-head basis this region has one of the heaviest diabetes burdens on earth, and it acquired most of it inside a single lifetime.
Why is diabetes so common in the Gulf?
Four factors, of which only the first gets talked about.
The transition happened extraordinarily fast. Most societies moved from scarcity to abundance, from walking to driving, and from manual work to office work across a century or more. Parts of the Gulf did it in about forty years. There are grandparents alive who grew up in an entirely different food and activity environment from their grandchildren. Genes calibrated to one set of conditions met a completely different set inside three generations, with no adjustment period.
The threshold for risk is lower here. This is the part most often missed. Populations from South Asia and the Middle East tend to develop insulin resistance at lower body mass indexes than European-origin populations, with more fat stored viscerally, around the organs, rather than under the skin. The practical consequence is that someone can look unremarkable, sit inside a normal BMI band, and still be metabolically in trouble. Guidance has begun to reflect this: the ADA's 2026 Standards use a BMI threshold of 27.5 rather than 30 for Asian American patients in some recommendations. A person here who is told their weight is fine may be being measured against the wrong yardstick.
The climate removes the default. In much of the world, incidental activity is free. You walk because walking is the obvious way to get somewhere. For a substantial part of the year in the Gulf, outdoor activity in the middle of the day is genuinely unsafe, and the built environment has been designed around that reality. Exercise here has to be a deliberate, scheduled, usually indoor decision, and anything that requires a decision happens less often than something that does not.
Diagnosis comes late. The IDF estimates that roughly 43 per cent of adults with diabetes worldwide are undiagnosed, overwhelmingly type 2. Type 2 is painless for years. Someone can carry it for a decade, accumulating damage to eyes, kidneys and nerves, and discover it only when a complication announces itself. Some of what looks like a treatment problem in regional statistics is actually a detection problem.
Does the demographic mix distort the figures?
It complicates them, and honest analysis has to say so.
The Gulf's population includes very large expatriate communities, particularly from South Asia, whose baseline susceptibility to type 2 diabetes is high. National prevalence figures are counts of who is in the country, not statements about any one nationality.
It also means the burden is not evenly distributed across the healthcare system. A large share of it sits with workers whose access to screening and continuing care is more limited, whose employment may not include comprehensive coverage, and who may leave the country before a complication is caught. That group barely appears in the clinic-based conversation about diabetes here, and they are among the people most exposed to it.
What does this cost?
More than the medication line suggests, and the expensive part is preventable.
Diabetes gets budgeted as a drug expense when the real spending is on complications. Dialysis for diabetic kidney disease, laser and injections for retinopathy, and above all the foot, where a single ulcer can lead to an amputation and a hospital stay that dwarfs years of tablets.
Every one of those is substantially preventable with screening that is cheap and boring. The economics of diabetes are the economics of doing dull things on schedule, and health systems everywhere are structurally bad at funding dull things on schedule.
What would actually move these numbers?
Three things, in descending order of impact and ascending order of political difficulty.
- Find the undiagnosed. If two in five people with this condition do not know, no treatment strategy can reach them. Opportunistic screening at any healthcare contact, including for workers outside the main insurance system, is the highest-yield intervention available.
- Screen for complications relentlessly. Annual eyes, annual feet, annual kidney function. None of it is glamorous and all of it is cheaper than what it prevents.
- Change the environment rather than lecturing about it. Individual advice has a poor record against a food supply and a built environment pushing the other way. Shaded walkable routes, indoor activity that is free rather than a gym membership, and reformulation of the sugar load in everyday drinks would do more than another awareness campaign.
The encouraging part is that this is not a mysterious condition. We know who gets it, why, and what prevents the worst of it. The gap here is not knowledge. It is the unglamorous work of doing the known thing, at scale, on time.
Published in The Outspoken Digest
Editorial desk
Outspoken Digest Health DeskMedicine, public health and the research behind the headlines, read carefully.
Newsletter
The Digest, in your inbox
One edition, sent when it is ready. No noise, and your address is never passed on.
Read Next
More Health →
The Same Word Is on Your Serum, Your Collagen Powder and the Vial Someone Is Selling on Telegram
Aug 20, 2026/4 min read

Retatrutide Is Not Approved in Any Country. It Is Also for Sale in Most of Them
Aug 20, 2026/4 min read

Retatrutide's Third Receptor Is the Hormone That Raises Blood Sugar. Adding It On Purpose Is the Whole Idea
Aug 20, 2026/4 min read

Diabetes Asks You to Make About 180 Decisions a Day, Then Calls You Non-Compliant When You Stop
Aug 18, 2026/4 min read